Which population of patients with CLL might benefit most from venetoclax plus ibrutinib?

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Nitin Jain, MD Anderson Cancer Center, Houston, US. We asked: Which population of patients with chronic lymphocytic leukemia might benefit most from venetoclax plus ibrutinib?

Nitin Jain discusses his study that investigated venetoclax plus ibrutinib as frontline treatment in patients with CLL with high-risk genetic markers. He explains MRD status was used to guide treatment, and that the combination treatment proved efficacious in that patient polulation.

CLL,venetoclax plus ibrutinib,Nitin Jain,ASH19,ASH 2019,Lymphoma Hub,lymphoma,del17p,tp53 mutation,del11q,